PATENT CLAIM ANALYSIS

Application Number: 15897032
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-10
Patent Classification: ["514", "001000"]

Abstract:
Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.

Claim (Index 20):
A method for the treatment of a hyperproliferative disorder comprising administering a therapeutic combination as a combined formulation or by alternation to a mammal, wherein the therapeutic combination comprises a therapeutically effective amount of GDC-0032 having the structure: and a therapeutically effective amount of a chemotherapeutic agent selected from 5-FU, docetaxel, eribulin, gemcitabine, GDC-0973, GDC-0623, paclitaxel, tamoxifen, fulvestrant, dexamethasone, pertuzumab, trastuzumab emtansine, trastuzumab and letrozole.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 88.0
- Lexical Diversity: 1.12
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13912281', '12208227', '12400988', '13109670', '15438277']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7914426223191199
- 35 USC 102 Novelty (BERT): 0.7640730992420779
- Combined Prediction Score: 0.7887056700114157
- Mean Citation Score: 568.5882720000002
- Max Citation Score: 967.9128
- Similarity Product: 887.2841114271638

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test